[go: up one dir, main page]

CN1261794A - 增溶的舍曲林组合物 - Google Patents

增溶的舍曲林组合物 Download PDF

Info

Publication number
CN1261794A
CN1261794A CN98806763A CN98806763A CN1261794A CN 1261794 A CN1261794 A CN 1261794A CN 98806763 A CN98806763 A CN 98806763A CN 98806763 A CN98806763 A CN 98806763A CN 1261794 A CN1261794 A CN 1261794A
Authority
CN
China
Prior art keywords
sertraline
solubilizing agent
compositions
acid
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98806763A
Other languages
English (en)
Chinese (zh)
Inventor
D·T·弗里森
S·M·赫比格
R·M·尚克
J·B·韦斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1261794(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1261794A publication Critical patent/CN1261794A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN98806763A 1997-07-01 1998-06-15 增溶的舍曲林组合物 Pending CN1261794A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01
US60/051,413 1997-07-01

Publications (1)

Publication Number Publication Date
CN1261794A true CN1261794A (zh) 2000-08-02

Family

ID=21971159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98806763A Pending CN1261794A (zh) 1997-07-01 1998-06-15 增溶的舍曲林组合物

Country Status (34)

Country Link
EP (1) EP0999829A1 (is)
JP (1) JP2000514100A (is)
KR (1) KR100366373B1 (is)
CN (1) CN1261794A (is)
AP (1) AP1192A (is)
AR (3) AR015917A1 (is)
AU (1) AU742535B2 (is)
BG (1) BG103918A (is)
BR (1) BR9810739A (is)
CA (1) CA2290974C (is)
CO (1) CO4940495A1 (is)
DZ (1) DZ2548A1 (is)
EA (1) EA002481B1 (is)
HN (1) HN1998000102A (is)
HR (1) HRP980377A2 (is)
HU (1) HUP0002236A3 (is)
ID (1) ID23429A (is)
IL (1) IL133076A (is)
IS (1) IS5260A (is)
MA (1) MA24587A1 (is)
NO (1) NO996520L (is)
OA (1) OA11243A (is)
PA (1) PA8454301A1 (is)
PE (1) PE97199A1 (is)
PL (1) PL337804A1 (is)
SK (1) SK181099A3 (is)
TN (1) TNSN98124A1 (is)
TR (1) TR199903297T2 (is)
TW (1) TW550087B (is)
UA (1) UA67741C2 (is)
UY (1) UY25071A1 (is)
WO (1) WO1999001120A1 (is)
YU (1) YU68299A (is)
ZA (1) ZA985708B (is)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺
CN114894736A (zh) * 2022-05-20 2022-08-12 中化地质矿山总局地质研究院 一种氯化物型卤水中硝酸根的测定方法
US12508313B2 (en) 2009-08-19 2025-12-30 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3227A1 (fr) 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
AP2001002264A0 (en) 2000-08-30 2001-09-30 Pfizer Prod Inc Sustained release formulations for growth hormone secretagogues.
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
EP2117652B1 (en) * 2007-03-12 2013-09-25 DSM IP Assets B.V. Cosmetic compositions
JPWO2011081117A1 (ja) * 2009-12-29 2013-05-09 興和株式会社 経口投与用固形医薬組成物
WO2011081118A1 (ja) * 2009-12-29 2011-07-07 興和株式会社 経口投与用医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
DE69004529T2 (de) * 1989-08-30 1994-02-24 Pfizer Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen.
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12508313B2 (en) 2009-08-19 2025-12-30 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺
CN114894736A (zh) * 2022-05-20 2022-08-12 中化地质矿山总局地质研究院 一种氯化物型卤水中硝酸根的测定方法

Also Published As

Publication number Publication date
AU7544898A (en) 1999-01-25
AR040279A2 (es) 2005-03-23
UY25071A1 (es) 2000-12-29
KR100366373B1 (ko) 2003-01-14
TW550087B (en) 2003-09-01
DZ2548A1 (fr) 2003-02-08
AP9801280A0 (en) 1998-06-30
UA67741C2 (uk) 2004-07-15
NO996520D0 (no) 1999-12-28
NO996520L (no) 2000-02-29
TNSN98124A1 (fr) 2005-03-15
BR9810739A (pt) 2000-09-12
HUP0002236A2 (hu) 2003-08-28
ZA985708B (en) 2000-01-10
WO1999001120A1 (en) 1999-01-14
CA2290974A1 (en) 1999-01-14
JP2000514100A (ja) 2000-10-24
AR015917A1 (es) 2001-05-30
IS5260A (is) 1999-11-19
IL133076A0 (en) 2001-03-19
CO4940495A1 (es) 2000-07-24
AU742535B2 (en) 2002-01-03
HN1998000102A (es) 1999-01-08
IL133076A (en) 2003-12-10
BG103918A (en) 2000-07-31
CA2290974C (en) 2004-04-27
HUP0002236A3 (en) 2003-12-29
EA199900962A1 (ru) 2000-08-28
EP0999829A1 (en) 2000-05-17
AP1192A (en) 2003-07-23
HRP980377A2 (en) 1999-04-30
TR199903297T2 (xx) 2000-07-21
EA002481B1 (ru) 2002-06-27
AR040280A2 (es) 2005-03-23
PA8454301A1 (es) 2000-09-29
MA24587A1 (fr) 1998-12-31
YU68299A (sh) 2002-06-19
SK181099A3 (en) 2000-07-11
KR20010013365A (ko) 2001-02-26
PE97199A1 (es) 1999-10-05
PL337804A1 (en) 2000-09-11
ID23429A (id) 2000-04-20
OA11243A (en) 2003-07-24

Similar Documents

Publication Publication Date Title
JP3403203B2 (ja) ダリフェナシン含有製剤
JP2002080398A (ja) ｐＨに依存する多相的な放出を伴う経口用の固体の薬学的組成物
CN1187052C (zh) 含有司他夫定(stavudine)的持续释放微球
CN1261794A (zh) 增溶的舍曲林组合物
US10258583B2 (en) Extended release liquid compositions of guanfacine
ES2852899T3 (es) Formulaciones estabilizadas de molindona
US7063864B1 (en) Morphine sulphate microgranules, method for preparing same and compositions containing same
EP1007024B1 (en) Delayed-release dosage forms of sertraline
PT1711169E (pt) Minicomprimidos revestidos de libertação prolongada de cloridrato de venlafaxina.
JP2646170B2 (ja) 徐放性塩酸オキシブチニン製剤
JP2002509887A (ja) セファクロル含有徐放性組成物
ES2321908T3 (es) Preparaciones farmaceuticas de liberacion prolongada independientemente del ph.
PT1618873E (pt) Grânulos para libertação controlada de tamsulosina, que contém alginato.
BR112021012259A2 (pt) Composição farmacêutica contendo hidrocloreto de tansulosina com excelente resistência a ácidos e método de preparação da mesma
HK1028881A (en) Solubilized sertraline compositions
CN1319004A (zh) 新的药用制剂
US20040208926A1 (en) Solubilized sertraline compositions
TWI361078B (en) Stabilized leukotriene b4 (ltb4) agent pharmaceutical formulation
NZ501250A (en) Solubilized sertraline compositions
CN1717252A (zh) 含有碱性药物的制剂
CZ464199A3 (cs) Solubilizované sertralinové kompozice
WO2024206692A1 (en) Brilaroxazine liposome composition
MXPA99012101A (en) Solubilized sertraline compositions
JP2812977B2 (ja) ポリプレニル系化合物含有硬カプセル剤の製造方法
FR2715067A1 (fr) Nouvelle forme galénique de dérivés de 5-nitro-imidazole efficace pour le traitement des parasitoses et des infections de l'ensemble du tractus gastro-intestinal.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1028881

Country of ref document: HK